CADILA HEALTHCARE | NATCO PHARMA | CADILA HEALTHCARE/ NATCO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 29.8 | 34.4 | 86.5% | View Chart |
P/BV | x | 4.8 | 4.9 | 98.0% | View Chart |
Dividend Yield | % | 0.7 | 0.7 | 104.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
NATCO PHARMA Mar-19 |
CADILA HEALTHCARE/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 849 | 41.5% | |
Low | Rs | 207 | 557 | 37.1% | |
Sales per share (Unadj.) | Rs | 139.2 | 573.8 | 24.3% | |
Earnings per share (Unadj.) | Rs | 11.8 | 176.0 | 6.7% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 198.2 | 9.4% | |
Dividends per share (Unadj.) | Rs | 3.50 | 6.25 | 56.0% | |
Dividend yield (eoy) | % | 1.3 | 0.9 | 140.9% | |
Book value per share (Unadj.) | Rs | 101.4 | 842.7 | 12.0% | |
Shares outstanding (eoy) | m | 1,023.74 | 36.50 | 2,804.8% | |
Bonus/Rights/Conversions | - | BB | - | ||
Price / Sales ratio | x | 2.0 | 1.2 | 163.8% | |
Avg P/E ratio | x | 23.7 | 4.0 | 594.6% | |
P/CF ratio (eoy) | x | 15.0 | 3.5 | 424.2% | |
Price / Book Value ratio | x | 2.8 | 0.8 | 330.5% | |
Dividend payout | % | 29.8 | 3.6 | 837.8% | |
Avg Mkt Cap | Rs m | 286,033 | 25,660 | 1,114.7% | |
No. of employees | `000 | 13.4 | 5.0 | 270.4% | |
Total wages/salary | Rs m | 24,145 | 3,559 | 678.4% | |
Avg. sales/employee | Rs Th | 10,632.7 | 4,225.3 | 251.6% | |
Avg. wages/employee | Rs Th | 1,801.2 | 718.0 | 250.9% | |
Avg. net profit/employee | Rs Th | 898.5 | 1,295.9 | 69.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 20,945 | 680.5% | |
Other income | Rs m | 1,139 | 1,302 | 87.5% | |
Total revenues | Rs m | 143,670 | 22,247 | 645.8% | |
Gross profit | Rs m | 24,198 | 7,948 | 304.5% | |
Depreciation | Rs m | 6,965 | 810 | 859.9% | |
Interest | Rs m | 3,418 | 193 | 1,771.0% | |
Profit before tax | Rs m | 14,954 | 8,247 | 181.3% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | 1,823 | 175.4% | |
Profit after tax | Rs m | 12,044 | 6,424 | 187.5% | |
Gross profit margin | % | 17.0 | 37.9 | 44.7% | |
Effective tax rate | % | 21.4 | 22.1 | 96.7% | |
Net profit margin | % | 8.5 | 30.7 | 27.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 23,472 | 371.3% | |
Current liabilities | Rs m | 82,694 | 7,287 | 1,134.8% | |
Net working cap to sales | % | 3.1 | 77.3 | 4.0% | |
Current ratio | x | 1.1 | 3.2 | 32.7% | |
Inventory Days | Days | 71 | 92 | 77.5% | |
Debtors Days | Days | 94 | 88 | 106.3% | |
Net fixed assets | Rs m | 133,236 | 18,648 | 714.5% | |
Share capital | Rs m | 1,024 | 365 | 280.5% | |
"Free" reserves | Rs m | 102,733 | 34,525 | 297.6% | |
Net worth | Rs m | 103,757 | 30,760 | 337.3% | |
Long term debt | Rs m | 32,146 | 0 | - | |
Total assets | Rs m | 236,866 | 43,031 | 550.5% | |
Interest coverage | x | 5.4 | 43.7 | 12.3% | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.5 | 123.6% | |
Return on assets | % | 6.5 | 15.4 | 42.5% | |
Return on equity | % | 11.6 | 20.9 | 55.6% | |
Return on capital | % | 13.7 | 27.4 | 50.0% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 52,752 | 11,536 | 457.3% | |
Fx outflow | Rs m | 14,504 | 2,939 | 493.5% | |
Net fx | Rs m | 38,248 | 8,597 | 444.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 6,688 | 374.6% | |
From Investments | Rs m | -10,123 | -6,122 | 165.4% | |
From Financial Activity | Rs m | -10,942 | -509 | 2,149.7% | |
Net Cashflow | Rs m | 3,989 | 66 | 6,043.9% |
Indian Promoters | % | 74.8 | 52.0 | 143.7% | |
Foreign collaborators | % | 0.0 | 1.5 | - | |
Indian inst/Mut Fund | % | 8.3 | 7.8 | 105.9% | |
FIIs | % | 5.9 | 16.6 | 35.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 26.0 | 42.3% | |
Shareholders | 44,069 | 25,395 | 173.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: PANACEA BIOTECH BIOCON UNICHEM LAB JUBILANT LIFE SCIENCES AJANTA PHARMA
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More